Jazz Pharmaceuticals (NASDAQ:JAZZ) Reaches New 12-Month High - Should You Buy?

Key Points

• Jazz Pharmaceuticals shares hit a new 52-week high of $208.15 (last at $207.61) on Monday, trading volume ~526,220 shares.
• Analysts collectively have a Moderate Buy consensus with an average price target of $216.87, and several firms recently raised their targets and ratings.
• Fundamentals are mixed: Q4 results beat estimates (EPS $6.64 vs. $6.49; revenue $1.20B, +8.1% YoY), but the company shows a negative net margin and insiders have sold roughly $14.2M of stock in the past three months.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) shares reached a new 52-week high during trading on Monday . The stock traded as high as $208.15 and last traded at $207.61, with a volume of 526220 shares traded. The stock had previously closed at $202.72.

Wall Street Analyst Weigh In

Several research analysts have recently commented on JAZZ shares. Royal Bank Of Canada boosted their price target on Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 25th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Jazz Pharmaceuticals in a research note on Friday, March 27th. Leerink Partners boosted their price objective on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 22nd. Raymond James Financial assumed coverage on shares of Jazz Pharmaceuticals in a research note on Friday, April 10th. They set an "outperform" rating and a $227.00 price objective for the company. Finally, Piper Sandler boosted their price objective on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an "overweight" rating in a research note on Thursday, March 19th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $216.87.

Jazz Pharmaceuticals Stock Up 2.6%

The company has a 50-day moving average of $189.65 and a 200-day moving average of $171.11. The company has a market capitalization of $13.05 billion, a price-to-earnings ratio of -34.85, a price-to-earnings-growth ratio of 0.35 and a beta of 0.27. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the company posted $6.51 EPS. The firm's quarterly revenue was up 8.1% compared to the same quarter last year. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post 20.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the transaction, the director owned 384,682 shares in the company, valued at approximately $73,281,921. This represents a 1.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Patricia Carr sold 1,287 shares of the company's stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $182.94, for a total transaction of $235,443.78. Following the transaction, the chief accounting officer owned 6,512 shares in the company, valued at $1,191,305.28. The trade was a 16.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 74,015 shares of company stock worth $14,180,486 in the last three months. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Hilltop National Bank acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $36,000. LRI Investments LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $38,000. Farther Finance Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 754.8% in the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company's stock valued at $35,000 after purchasing an additional 234 shares during the period. Leonteq Securities AG acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $50,000. Finally, Root Financial Partners LLC increased its stake in shares of Jazz Pharmaceuticals by 42.8% in the first quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company's stock worth $56,000 after acquiring an additional 89 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.